Análisis de aceros AHSS en el nuevo simulador de deformación plástica HSMFS

El presente documento muestra las capacidades del nuevo simulador de deformación plástica, de reciente construcción, y capaz de realizar ensayos en cualquier tipo de material, hasta una fuerza de 10 kN. Además, se exponen otras líneas de investigación del grupo.Sellés Cantó, MÁ.; Sanchez-Caballero, S.; Pla-Ferrando, R.; Reig Pérez, MJ.; Segui Llinares, VJ.; Eixerés Tomás, B.; Pérez Bernabeu, E. (2013). Análisis de aceros AHSS en el nuevo simulador de deformación plástica HSMFS. Compobell, S.L. http://hdl.handle.net/10251/73772

Passive Safety evaluation in driving adapted vehicles

[EN] Driving a private vehicle represents nowadays one of the most viable ways by which disabled drivers can maintain their mobility and transport conditions. To do so it is necessary to adapt a vehicle to the user's residual capabilities. Nevertheless the technical aids installed in the vehicles must fulfill the same safety requirements as standard vehicles. This paper shows the results of a research project held at the Automobile Laboratory of the Technical University of Valencia (Spain), the main objective being to generate basic design criteria for improving the passive safety behaviour of the adapted vehicle under different impact conditions.The research project whose partial results are shown in this paper was developed by the Automobile Laboratory of the Technical University of Valencia (Spain), under the auspices of the Spanish Ministry of Science and Innovation (Ref. TRA2005-08649) during the years 2006–2008.Dols Ruiz, JF.; Masiá Vañó, J.; Eixerés Tomás, B. (2012). Passive Safety evaluation in driving adapted vehicles. International Journal of Vehicle Safety. 6(1):77-89. doi:10.1504/IJVS.2012.048534S77896

Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study with retrospective analysis of a cohort of MSSA IE treated with cloxacillin and/or cefazolin. Outcomes assessed were relapse; intra-hospital, overall, and endocarditis-related mortality; and adverse events. Risk of renal toxicity with each treatment was evaluated separately. Results: We included 631 IE episodes caused by MSSA treated with cloxacillin and/or cefazolin. Antibiotic treatment was cloxacillin, cefazolin, or both in 537 (85%), 57 (9%), and 37 (6%) episodes, respectively. Patients treated with cefazolin had significantly higher rates of comorbidities (median Charlson Index 7, P <0.01) and previous renal failure (57.9%, P <0.01). Patients treated with cloxacillin presented higher rates of septic shock (25%, P = 0.033) and new-onset or worsening renal failure (47.3%, P = 0.024) with significantly higher rates of in-hospital mortality (38.5%, P = 0.017). One-year IE-related mortality and rate of relapses were similar between treatment groups. None of the treatments were identified as risk or protective factors. Conclusion: Our results suggest that cefazolin is a valuable option for the treatment of MSSA IE, without differences in 1-year mortality or relapses compared with cloxacillin, and might be considered equally effective